| Followers | 74 |
| Posts | 3922 |
| Boards Moderated | 0 |
| Alias Born | 03/23/2013 |
Monday, February 02, 2026 12:07:24 PM
Most have ignored me (haha), that's ok, most weak stemmed humans ignore the voice of reason when intoxicated by FOMO.
For what it's worth though (probably 2 nasty emojis from DMC8), as you all know, AMRN - for the most part - has lost it's upside coupling with the biotech index due to it's absence in the ETF. However, if the index drops, so does AMRN - by virtue of its presence int the biotech group (The tide drops all boats). As a result, absent earthshattering news, the stock will likely mirror the performance of the index. So what will the index look like on 12/31?
Not good from a TA perspective based on the XBI chart:
From 2020-2022, the index traced a parabolic pattern. Since then it struggled to retrace and only until this past year was it able to trace back to major overhead resistance - coinciding with 50% retracement level of the Eifel Tower back side. Soon, it will begin to eat its gains and slump back to the pink highest volume by price shaded area. This scenario will make it hard for AMRN to swim upstream against the current.
Now for AMRN:
This is a weekly chart showing levels of resistance and support. If the index is under pressure, the shorts are not. Buyers, aside from retail double downers, are virtually absent - complements of the 20 for 1 reverse split. The split news serves as a magnet for bears especially if the index rolls over and they come hunting amongst the weak stocks of the index. As a result, we will see sideways at best with a downward fade into the year end due to year-end tax loss sellers who were caught long at higher prices from chasing the recent rally to 20 (top of the blue shaded area).
Finally, my short term TA analysis (It presents a setup for a great short trade, but very poor long trade):
Bulls have made repeated attempts by stabbing prices up through the pink shaded area of resistance, only to be met with failure. This is absorption of the buying be sellers at that level. The supply is too much to overcome for now. This means that at some point, buyers dry up and the supply overwhelms prices lower until demand halts the slide. Where will that demand come from? Institutions? Hedge funds? Retail? Not likely if the index slumps.
I don't think current holders of the stock really appreciate the long term ramifications of the reverse split.
1) It chased away 'big money'
2) It decreased the float making prices volatile and vulnerable to wide swings - especially bear raids.
3) It took the share buyback operation off the table.
4) It screamed desperation because it was the only means to avoid delisting. That doesn't attract too many buyers.
I know the above sounds awful but if you can dispute the logic with reason, I'm all ears. IMO it is objective and a likely outcome unless R-IT type news drops. It will take something like that to lift prices out of this Kondratieff Winter pattern.
Recent AMRN News
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients • GlobeNewswire Inc. • 11/09/2025 09:15:00 PM
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2025 08:30:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2025 11:05:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2025 11:05:27 AM
- Amarin Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 10/29/2025 11:00:00 AM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
